Roche

Healthcare scenario in MENA region
Booming Healthcare sector in MENA: Lucrative opportunity for Global pharma players

The Middle-East and North-Africa region (MENA), which encompasses some of the world’s wealthiest economies, extends unparalleled opportunities to multinational corporations with expertise in medic...


pharma news
Roche, Sarepta collaborates; FDA approval for Merck’s Ervebo, and Allergan’s Ubrelvy

Roche has entered into a licensing partnership with Sarepta Therapeutics worth USD 1.15 Billion.  Roche has agreed to license in Sarepta’s gene therapy ‘SRP-9001’ for Duchenne muscular dys...


Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval
Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval

Bristol-Meyers Squibb and Acceleron Pharma have announced that US FDA committee will review BMS’s supplemental Biologics License Application (sBLA) for its Reblozyl in MDS. Reblozyl ((luspater...


Pharma News
Novartis buys Medicines Co. for USD 9.7 Billion

Novartis plans to buy The Medicines Company for USD 9.7 Billion to gain access to a heart drug inclisiran, almost ready to get into the market. Under the terms of the deal, Novartis will pay U...


Recent Pharma News
Roche’s Tecentriq combo proves effective in Bladder cancer

Roche’s Genentech has presented positive Phase III results from the IMvigor130 study aimed at studying Tecentriq (atezolizumab) tested in combination with platinum-based chemotherapy. The drug...


Lupus Nephritis
Roche’s Gazyva receives FDA Breakthrough designation for Lupus nephritis

The US FDA has in a recent move granted Roche’s Gazyva Breakthrough Therapy Designation (BTD) for adults with lupus nephritis. Gazyva (obinutuzumab) is an anti-cancer ("antineoplastic" or "cyto...


breast cancer emerging drugs
How HR+/ HER2-Breast Cancer emerging drugs will transform the market?

More than a dozen companies have shifted their focus towards the Hormone Receptor positive (HR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer therapeutic area. Some of ...


HR+/HER2- Breast Cancer
Global HR+/ HER2- Breast Cancer Market Scenario

Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer is the most prevalent form of breast cancer. This type accounts for a higher percentage among all breast ca...


Systemic sclerosis
FDA approves Ofev for interstitial lung disease

Recently, the US FDA has approved a new drug therapy to treat adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. Ofev (nintedanib) capsules, t...


HER2-Positive Breast Cancer
Metastatic HER2-Positive Breast Cancer

Breast cancer is not a single disease leading to abnormal cell division in breast tissues. In the United States, it is estimated that more than 40,000 women will die from breast cancer in 2017. Ac...


Editor's Pick
Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...

The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...

Emerging Market for Organ on a Chip

The organ on a chip is a microfluidic culture device that recapitulates the complicated...

Global Top Players in Intraocular Lens (IOL) Market

 An Intraocular Lens implant is a synthetic, artificial lens placed inside the eye...

Investigating the Pipeline for Ankylosing Spondylitis Treatment Landscape

Ankylosing Spondylitis is a form of arthritis that primarily affects the spine. It caus...

LAG 3: A Promising Next Generation Cancer Immunotherapy

Immunotherapy also called biologic therapy, is a type of cancer treatment that boosts t...

ASCO Conference 2022
ASCO Conference 2022

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.